| Literature DB >> 24102036 |
Shokouh Taghipour Zahir1, Fariba Binesh, Mehrdad Mirouliaei, Elias Khajeh, Sina Noshad.
Abstract
Purpose. We sought to investigate the utility of classification and regression trees (CART) classifier to differentiate benign from malignant nodules in patients referred for thyroid surgery. Methods. Clinical and demographic data of 271 patients referred to the Sadoughi Hospital during 2006-2011 were collected. In a two-step approach, a CART classifier was employed to differentiate patients with a high versus low risk of thyroid malignancy. The first step served as the screening procedure and was tailored to produce as few false negatives as possible. The second step identified those with the lowest risk of malignancy, chosen from a high risk population. Sensitivity, specificity, positive and negative predictive values (PPV and NPV) of the optimal tree were calculated. Results. In the first step, age, sex, and nodule size contributed to the optimal tree. Ultrasonographic features were employed in the second step with hypoechogenicity and/or microcalcifications yielding the highest discriminatory ability. The combined tree produced a sensitivity and specificity of 80.0% (95% CI: 29.9-98.9) and 94.1% (95% CI: 78.9-99.0), respectively. NPV and PPV were 66.7% (41.1-85.6) and 97.0% (82.5-99.8), respectively. Conclusion. CART classifier reliably identifies patients with a low risk of malignancy who can avoid unnecessary surgery.Entities:
Year: 2013 PMID: 24102036 PMCID: PMC3786504 DOI: 10.1155/2013/983953
Source DB: PubMed Journal: J Thyroid Res
Descriptive characteristics of 271 patients referred for thyroid nodule evaluation between 2006 and 2011.
| Benign | Malignant |
| Total | |
|---|---|---|---|---|
| Age (years) | 0.008 | |||
| <30 | 37 (19.0) | 20 (26.3) | 57 (21.0) | |
| ≥30 and ≤60 | 135 (69.2) | 38 (50.0) | 173 (63.8) | |
| >60 | 23 (11.8) | 18 (23.7) | 41 (15.2) | |
| Sex (women/men) | 167/28 | 55/21 | 0.011 | 222/49 |
| Thyroid enlargement, | 110 (56.4) | 46 (60.5) | 0.538 | 156 (57.6) |
| Number of nodules, | 0.191 | |||
| Single | 182 (93.3) | 74 (97.4) | 256 (94.5) | |
| Multiple | 13 (6.7) | 2 (2.6) | 15 (5.5) | |
| Nodule size, | <0.001 | |||
| <2 cm | 4 (2.1) | 10 (13.2) | 15 (5.5) | |
| 2–5 cm | 128 (65.6) | 52 (68.4) | 179 (66.0) | |
| >5 cm | 63 (32.3) | 14 (18.4) | 77 (28.5) | |
| TFT, | 0.288 | |||
| Hyperthyroid | 9 (4.6) | 2 (2.6) | 11 (4.1) | |
| Euthyroid | 139 (71.3) | 49 (64.5) | 188 (69.4) | |
| Hypothyroid | 47 (24.1) | 25 (32.9) | 72 (26.5) | |
| FNA, results | <0.001 | |||
| Nondiagnostic | 16 (8.2) | 7 (9.2) | 23 (8.5) | |
| Benign | 44 (22.5) | 8 (10.5) | 52 (19.2) | |
| Indeterminate | 85 (43.6) | 8 (10.5) | 93 (34.3) | |
| Suspicious | 46 (23.6) | 12 (15.8) | 58 (21.4) | |
| Malignant | 4 (2.1) | 41 (54.0) | 45 (16.6) |
Abbreviations: TFT: thyroid function test; FNA: fine needle aspiration.
Figure 1Smoothed association of age with thyroid cancer (non-linear P = 0.004).
Figure 2Smoothed association of nodule size with thyroid cancer (non-linear P = 0.220).
Pathologic diagnoses of thyroid nodules evaluated between 2006 and 2011.
| Benign | |
| Multinodular goiter | 133 (68.3) |
| Follicular adenoma | 40 (20.5) |
| Lymphocytic thyroiditis | 9 (4.6) |
| Hashimoto's thyroiditis | 8 (4.1) |
| Hurthle cell adenoma | 3 (1.5) |
| Graves' disease | 2 (1.0) |
|
|
|
|
| |
| Malignant | |
| Papillary cell carcinoma | 59 (77.7) |
| Follicular cell carcinoma | 8 (10.5) |
| Medullary cell carcinoma | 5 (6.6) |
| Hurthle cell carcinoma | 2 (2.6) |
| Anaplastic Carcinoma | 2 (2.6) |
|
|
|
Sensitivity, specificity, and positive and negative predictive values of the optimal tree in discriminating benign from malignant pathologies.
| Learning sample ( | Test sample ( | Test sample with nondiagnostic, indeterminate, or suspicious FNA ( | |
|---|---|---|---|
| First step | |||
| Sensitivity | 94.4 (84.9–98.1) | 91.3 (70.5–98.5) | 100.0 (46.3–1.0) |
| Specificity | 65.4 (57.1–72.9) | 56.9 (43.3–69.6) | 61.8 (43.6–77.3) |
| PPV | 52.1 (41.8–62.1) | 45.7 (31.2–60.8) | 27.8 (10.7–53.6) |
| NPV | 96.7 (90.1–99.1) | 94.3 (79.5–99.0) | 100.0 (80.8–1.0) |
| Second step | |||
| Sensitivity | 82.3 (68.6–91.1) | 76.2 (52.4–90.9) | 80.0 (29.9–98.9) |
| Specificity | 91.5 (78.7–97.2) | 84.0 (63.1–94.7) | 84.6 (53.7–97.3) |
| PPV | 91.3 (78.3–97.2) | 80.0 (55.7–93.4) | 66.7 (41.1–85.6) |
| NPV | 82.7 (69.2–91.3) | 80.8 (60.0–92.7) | 91.7 (59.7–99.6) |
| Decision tree | |||
| Sensitivity | 77.8 (64.1–87.5) | 69.6 (47.0–85.9) | 80.0 (29.9–98.9) |
| Specificity | 97.1 (92.2–99.0) | 93.1 (82.4–97.8) | 94.1 (78.9–99.0) |
| PPV | 91.3 (78.3–97.2) | 80.0 (55.7–93.4) | 66.7 (41.1–85.6) |
| NPV | 91.7 (85.6–95.4) | 88.5 (77.2–94.5) | 97.0 (82.5–99.8) |
Abbreviations: FNA: fine needle aspiration; PPV: positive predictive value; NPV: negative predictive value.
Figure 3Optimal decision tree for stratifying patients based on their risk for thyroid cancer. Subjects categorized in the gray boxes (high-risk patients) in the first step are reevaluated in the second step using US findings. Syntax: if nodule size ≤2 cm and hypoechogenicity/microcalcification → high risk. If size >2 cm and (age <30 or >60) and hypoechogenicity/microcalcification → high risk. If (2≤ size ≤5) and (30≤ age ≤60) and male sex and hypoechogenicity/microcalcification → high risk. Otherwise → low risk.